00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
13:54 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

DISEASE CATEGORY: Cancer INDICATION: Lymphoma Cell culture studies identified a diazooxohexanoate-based prodrug of a GLS inhibitor that could help treat lymphoma. Chemical synthesis and screening of ester prodrugs of the GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) in...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
15:18 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1,...
17:39 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
18:47 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Evolus’ prabotulinumtoxinA meets in head-to-head Phase III for glabellar lines

Evolus Inc. (NASDAQ:EOLS) reported data from the Phase III EVB-003 trial in 540 patients with moderate to severe glabellar lines (frown lines between the eyebrows) showing that a single dose of 20 U prabotulinumtoxinA (DWP-450)...
19:02 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest the GLS inhibitor CB-839 could help treat KRAS-mutant lung cancers that also harbor KEAP1 mutations. In a mouse model of KRAS- and KEAP1-mutant lung cancer, the...